Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib, and the progressive disease is often quite a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905592/
https://www.ncbi.nlm.nih.gov/pubmed/33627156
http://dx.doi.org/10.1186/s13045-021-01039-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905592/
https://www.ncbi.nlm.nih.gov/pubmed/33627156
http://dx.doi.org/10.1186/s13045-021-01039-9

Ejemplares similares